• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by AVROBIO, Inc.

< Previous 1 2 Next >
AVROBIO Announces Preclinical Gene Therapy Data for Pompe Disease at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
May 18, 2022
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO Reports Positive Data From Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis, Including New Interim Data on Neurocognitive Measures
May 17, 2022
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO to Present at the H.C. Wainwright Global Investment Conference
May 16, 2022
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 06, 2022
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO to Present New Clinical and Preclinical Data at the ASGCT 25th Annual Meeting
May 03, 2022
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 06, 2022
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO to Present at the 21st Annual Needham Virtual Healthcare Conference
April 05, 2022
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Update
March 17, 2022
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO Reports Interim Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis
February 09, 2022
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 04, 2022
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO Announces the Appointment of Sean O’Bryan as Chief Regulatory Officer
February 01, 2022
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO to Present at Cowen’s 2nd Annual Genetic Medicines Summit
January 28, 2022
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO to Present New Data from Phase 1/2 Clinical Trial in Cystinosis at WORLDSymposium™ 2022
January 27, 2022
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 06, 2022
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO Reprioritizes Pipeline Programs
January 04, 2022
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 07, 2021
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO Presents Clinician Experience with FAB-GT Clinical Trial and Updated Safety Data for Investigational Gene Therapies in Fabry Disease and Gaucher Disease Type 1
November 24, 2021
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO to Present at Two Upcoming Investor Conferences in November
November 09, 2021
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO to Present Clinical and Preclinical Data at the 14th ICIEM Conference
November 08, 2021
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 05, 2021
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO Reports Third Quarter 2021 Financial Results and Provides Business Update
November 04, 2021
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO Receives Rare Pediatric Disease Designation from the U.S. FDA for AVR-RD-05, a Gene Therapy for Mucopolysaccharidosis Type II (MPSII) or Hunter Syndrome
November 03, 2021
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO Announces the Appointment of Essra Ridha, M.D., MRCP, FFPM, as Chief Medical Officer
October 26, 2021
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO to Present at the Jefferies Virtual Gene Therapy/Editing Summit
October 20, 2021
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO Reports New Interim Safety Data Across Investigational Gene Therapies for Fabry and Gaucher Disease Type 1
October 19, 2021
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO to Present New Clinical and Preclinical Data Across Multiple Programs at the ESGCT 28th Annual Congress
October 06, 2021
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 05, 2021
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 03, 2021
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO to Participate at Four Upcoming Investor Conferences
September 01, 2021
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO Reports Second Quarter 2021 Financial Results and Provides Business Update
August 05, 2021
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap